Photocure announces grant of new European patent for Cevira®

Published: 22 September 2015Product Announcements

Oslo, September 22, 2015 - Photocure (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in cancer and dermatology today announces that a new patent for Cevira has been granted in Europe.

Cevira is one of Photocure's promising pipeline products and is being developed as a new and innovative breakthrough for the treatment of precancerous lesions of the cervix. The newly granted patent protects the Cevira device including its use in combination with the Cevira drug until 2029.

This key patent in Photocure's Cevira portfolio complements the company's proprietary European patent, which claims different aspects of the Cevira device and Photocure's registered European Community design, which covers the appearance of the device, i.e. lines, contours, colours, shape, texture and/or materials. The patent expires in 2029, while the design expires in April 2038. In US, Photocure has patents granted to 2030.

The approval of this latest patent is a key milestone for us in our continued work to secure the long-term value of Cevira. The new patent further strengthens Photocure's robust patent portfolio and provides Cevira market exclusivity for the long-term. Cevira is a key asset for us, with the potential to not only treat HPV induced cervical high grade disease but also to prevent the development of cervical cancer, which affects more than 500,000 women annually." said Kjetil Hestdal, President and CEO of Photocure.

For further information, please contact:

President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email:
CFO Erik Dahl
Tel: +47 450 55 000, Email:

Notes to editors

About Photocure ASA
Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company and world leader in photodynamic technology. Based on our unique proprietary Photocure Technology(TM) platform, Photocure develops and commercializes highly selective and effective solutions within disease areas with high unmet medical need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal cancer and skin conditions. Our aim is to provide solutions which can improve health outcomes for patients worldwide. Photocure is listed on the Oslo Stock Exchange (OSE: PHO). Information about Photocure is available at

About Cevira®
Cevira® is being developed as an intravaginal drug-device combination with an integrated light source based on Photocure Technology(TM) for the treatment of HPV and precancerous cervical lesions.

This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events